Barclays
EOLS icon

Barclays’s Evolus EOLS Stock Holding History

Barclays’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115K Sell
27,878
-102,860
-79% -$498K ﹤0.01% 3971
2025
Q4 		$869K Buy
130,738
+24,845
+23% +$168K ﹤0.01% 3537
2025
Q3 		$650K Sell
105,893
-12,996
-11% -$101K ﹤0.01% 3630
2025
Q2 		$1.09M Buy
118,889
+39,528
+50% +$404K ﹤0.01% 3280
2025
Q1 		$955K Sell
79,361
-26,425
-25% -$346K ﹤0.01% 3137
2024
Q4 		$1.17M Buy
105,786
+12,124
+13% +$170K ﹤0.01% 3276
2024
Q3 		$1.52M Buy
93,662
+68,213
+268% +$953K ﹤0.01% 3074
2024
Q2 		$276K Sell
25,449
-17,138
-40% -$211K ﹤0.01% 3391
2024
Q1 		$596K Sell
42,587
-26,870
-39% -$349K ﹤0.01% 3479
2023
Q4 		$731K Buy
69,457
+49,663
+251% +$444K ﹤0.01% 3655
2023
Q3 		$181K Buy
19,794
+3,889
+24% +$34.9K ﹤0.01% 3345
2023
Q2 		$116K Sell
15,905
-2,065
-11% -$17.8K ﹤0.01% 3502
2023
Q1 		$152K Buy
17,970
+8,461
+89% +$76.5K ﹤0.01% 3952
2022
Q4 		$71.4K Sell
9,509
-423
-4% -$3.28K ﹤0.01% 4409
2022
Q3 		$80K Sell
9,932
-13,641
-58% -$145K ﹤0.01% 3615
2022
Q2 		$274K Buy
23,573
+12,735
+118% +$150K ﹤0.01% 3254
2022
Q1 		$121K Sell
10,838
-39,383
-78% -$336K ﹤0.01% 3697
2021
Q4 		$327K Buy
50,221
+15,872
+46% +$109K ﹤0.01% 3381
2021
Q3 		$262K Buy
34,349
+25,134
+273% +$260K ﹤0.01% 3478
2021
Q2 		$117K Sell
9,215
-8,985
-49% -$98.8K ﹤0.01% 3789
2021
Q1 		$237K Sell
18,200
-1,113
-6% -$10.3K ﹤0.01% 3628
2020
Q4 		$65K Buy
19,313
+9,280
+92% +$34.8K ﹤0.01% 4306
2020
Q3 		$39K Sell
10,033
-1,986
-17% -$7.25K ﹤0.01% 4712
2020
Q2 		$64K Buy
12,019
+5,883
+96% +$27.1K ﹤0.01% 4794
2020
Q1 		$26K Sell
6,136
-12,337
-67% -$105K ﹤0.01% 5549
2019
Q4 		$225K Buy
18,473
+4,987
+37% +$70.3K ﹤0.01% 4946
2019
Q3 		$210K Sell
13,486
-4,761
-26% -$78K ﹤0.01% 4922
2019
Q2 		$266K Buy
18,247
+2,821
+18% +$55.9K ﹤0.01% 4855
2019
Q1 		$348K Buy
15,426
+9,171
+147% +$198K ﹤0.01% 4409
2018
Q4 		$75K Sell
6,255
-17,375
-74% -$248K ﹤0.01% 5234
2018
Q3 		$439K Buy
23,630
+17,922
+314% +$388K ﹤0.01% 4382
2018
Q2 		$159K Buy
5,708
+4,363
+324% +$77K ﹤0.01% 4912
2018
Q1 		$12K Buy
+1,345
New +$15.4K ﹤0.01% 6599

Other funds holding EOLS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's EOLS Position: Q1 2026 in Review

Barclays reduced its Evolus (EOLS) stake by 79% in Q1 2026, selling an estimated $498K and leaving 27,878 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #3971.

Barclays first reported a position in EOLS in Q1 2018 and has held it in 33 quarters since. The position peaked at $1.52M in Q3 2024. 147 funds tracked by Wall St. Rank hold EOLS as of Q1 2026.

  • Barclays held 27,878 shares of Evolus worth $115K as of Q1 2026.
  • Barclays sold 102,860 Evolus shares in Q1 2026, an estimated $498K.
  • Evolus made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3971 holding.
  • Barclays first reported a position in Evolus in Q1 2018 and has held it in 33 quarters since.
  • Barclays's Evolus position peaked at $1.52M in Q3 2024.
  • 147 funds tracked by Wall St. Rank held Evolus as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.